enGene Holdings Inc. Common Stock (ENGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.92 (+0.52%), Market cap $0.12B, 52-week low–high $1.44 ~ $12.17.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Financial statements, price targets, institutional (13F) holdings and related news for enGene Holdings Inc. Common Stock are updated in real time on BlackAll Trade.
enGene Holdings Inc. Common Stock trades at $1.92 (+0.52%). Real-time quotes and charts are available on BlackAll Trade.
enGene Holdings Inc. Common Stock has a market cap of about $0.12B.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from blad